```html

Huntington Disease: A Complete Medical Guide

Overview

Huntington disease (HD) is a progressive, inherited neurodegenerative disorder that damages specific brain regions, leading to uncontrolled movements, cognitive decline, and psychiatric problems. It is caused by a mutation in the HTT gene, which creates an abnormally long stretch of CAG repeats in the huntingtin protein.

HD typically appears in mid‑adulthood (average onset 35‑45 years), but symptoms can begin in childhood (juvenile HD) or much later in life. The disease is autosomal‑dominant, meaning a child of an affected parent has a 50 % chance of inheriting the mutation.

Prevalence: Approximately 5‑10 per 100,000 people of European ancestry carry the mutation; worldwide prevalence is about 0.004 % of the population. In the United States, ~30,000 people are estimated to have HD, with another 200,000 at risk of inheriting the gene (CDC, 2023).

Symptoms

Symptoms are grouped into three domains – motor, cognitive, and psychiatric. They appear gradually and worsen over 10‑25 years.

Motor

• Chorea – brief, involuntary, jerky movements of the face, limbs, and trunk.
• Dystonia – sustained muscle contractions causing abnormal postures.
• Impaired coordination (ataxia) – difficulty walking, frequent falls.
• Bradykinesia – slowed movement, similar to Parkinson’s disease.
• Oro‑facial dyskinesia – difficulty swallowing, speaking, or controlling tongue movements.

Cognitive

• Reduced attention and concentration.
• Difficulty with planning, organizing, and multitasking.
• Impaired insight – patients may not recognize their own deficits.
• Progressive memory loss; eventually leads to dementia.

Psychiatric

• Depression and anxiety (most common).
• Irritability, aggression, or hostility.
• Obsessive‑compulsive behaviors.
• Psychosis (hallucinations, delusions) in later stages.
• Suicidal thoughts – risk is 10‑20 % higher than the general population.

Other Common Features

• Weight loss despite normal or increased caloric intake (due to higher metabolic demand and swallowing problems).
• Sleep disturbances – insomnia, restless leg syndrome.
• Loss of bladder control in advanced disease.

Causes and Risk Factors

The root cause is a genetic mutation:

• Genetic mutation: Expansion of CAG repeats in the HTT gene on chromosome 4. Normal alleles have ≤ 35 repeats; disease‑causing alleles have ≥ 36 repeats. The greater the repeat length, the earlier the onset (anticipation).
• Inheritance pattern: Autosomal‑dominant. Each child of an affected parent has a 50 % chance of inheriting the mutation, regardless of sex.

Risk factors are largely genetic, but other factors can influence disease expression:

• Family history of HD.
• CAG repeat length – > 60 repeats often leads to juvenile onset.
• Ethnicity – most common in people of European descent; rare in Asian and African populations.

Diagnosis

Because symptoms overlap with other movement disorders, a thorough diagnostic work‑up is essential.

Clinical Evaluation

• Detailed medical and family history (focus on neuropsychiatric disorders).
• Neurological exam assessing chorea, coordination, gait, and reflexes.
• Mental‑status testing for cognition and mood.

Genetic Testing

DNA analysis for CAG repeat expansion is the definitive test. It is usually performed on a blood sample. Pre‑ and post‑test genetic counseling is recommended because of the psychological impact of results.

Neuroimaging

• MRI – shows caudate nucleus atrophy and ventricular enlargement in later stages.
• CT scan – less sensitive but may be used if MRI is unavailable.

Other Tests

• Baseline labs (CBC, metabolic panel) to rule out metabolic causes of movement disorders.
• Psychiatric screening tools (PHQ‑9, Beck Anxiety Inventory) to identify co‑existing mood disorders.

Treatment Options

There is currently no cure that stops the genetic process, but a combination of medications, therapy, and lifestyle adjustments can alleviate symptoms and improve quality of life.

Medications

• Tetrabenazine (Xenazine) – FDA‑approved to reduce chorea; may cause depression, so monitor mood closely.
• Deutetrabenazine (Austedo) – longer‑acting variant with similar efficacy but fewer dosing fluctuations.
• Antipsychotics – risperidone, olanzapine, or haloperidol for severe chorea, psychosis, or agitation.
• Antidepressants – SSRIs (sertraline, fluoxetine) for depression and anxiety.
• Anti‑seizure drugs – may help with dystonia or myoclonus (e.g., clobazam).
• Botulinum toxin injections – targeted for focal dystonia or severe muscle cramps.

Procedures & Interventions

• Deep Brain Stimulation (DBS) – experimental in select centers; may improve motor control in advanced chorea.
• Speech and Swallowing Therapy – to reduce aspiration risk.
• Physical & Occupational Therapy – maintain mobility, prevent contractures, and teach adaptive equipment use.

Lifestyle & Supportive Care

• Balanced, high‑calorie diet with small, frequent meals; consider supplements if weight loss is significant.
• Regular aerobic exercise (walking, swimming) to preserve motor function and mood.
• Structured daily routine – reduces anxiety and cognitive overload.
• Engagement in cognitive‑stimulating activities (puzzles, music, reading).
• Advance care planning – discuss legal, financial, and end‑of‑life preferences early.
• Join support groups (Huntington’s Disease Society of America, local chapters).

Living with Huntington Disease

Managing HD requires a multidisciplinary approach involving the patient, family, and healthcare team.

Practical Daily Tips

• Safety first: Install grab bars, non‑slip mats, and wearable alarms to prevent falls.
• Medication management: Use pill organizers or automated dispensers.
• Communication strategies: Speak slowly, use simple sentences, give extra time to respond.
• Caregiver support: Rotate caregiving duties, schedule respite care, and seek counseling.
• Financial planning: Apply for disability benefits early (Social Security, VA). Explore long‑term care insurance.
• Legal documents: Create an advance directive, power of attorney, and living will while decision‑making capacity remains intact.

Emotional & Social Well‑Being

• Encourage participation in social activities that match current abilities.
• Mindfulness, meditation, and yoga can mitigate anxiety and depression.
• Professional counseling for both patient and family is highly recommended.

Prevention

Because HD is a genetic disorder, primary prevention (stopping the disease from occurring) is not possible. However, certain steps can reduce the impact on future generations:

• Genetic counseling: Individuals with a family history should meet a certified genetic counselor before having children.
• Reproductive options: Pre‑implantation genetic diagnosis (PGD) with in‑vitro fertilization allows selection of embryos without the mutation.
• Prenatal testing: Chorionic villus sampling or amniocentesis can diagnose HD in utero.
• Research participation: Enrolling in clinical trials (e.g., gene‑silencing therapies) contributes to future disease‑modifying strategies.

Complications

If untreated or poorly managed, HD can lead to serious health problems:

• Severe functional decline: Loss of ability to walk, speak, or swallow.
• Aspiration pneumonia: Due to swallowing dysfunction; a leading cause of death.
• Malnutrition and dehydration.
• Weight loss and muscle wasting.
• Falls and fractures.
• Severe depression or suicidal behavior.
• Cardiovascular complications: Reduced physical activity can increase risk of hypertension and heart disease.

When to Seek Emergency Care

References

1. Mayo Clinic. Huntington disease. 2023. https://www.mayoclinic.org
2. CDC. Huntington Disease. 2023. https://www.cdc.gov
3. National Institute of Neurological Disorders and Stroke (NINDS). Huntington’s Disease Information Page. 2022. https://www.ninds.nih.gov
4. World Health Organization. Genetic Counseling Guidelines. 2021.
5. Cleveland Clinic. Huntington’s disease: Treatment & Management. 2023. https://my.clevelandclinic.org
6. Roos RA, et al. “Huntington disease: Clinical features and management.” Nature Reviews Neurology. 2022;18:215‑227.

```